Cited by 1,569RNA modifications and cancerRNA regulation and diseaseRNA and protein synthesis mechanisms

Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome

Open access
Linder, Bastian, Grozhik, Anya V, Olarerin-George, Anthony O, Meydan, Cem, Mason, Christopher E, Jaffrey, Samie R·2015·Nature Methods

Abstract

N(6)-methyladenosine (m6A) is the most abundant modified base in eukaryotic mRNA and has been linked to diverse effects on mRNA fate. Current mapping approaches localize m6A residues to transcript regions 100-200 nt long but cannot identify precise m6A positions on a transcriptome-wide level. Here we developed m6A individual-nucleotide-resolution cross-linking and immunoprecipitation (miCLIP) and used it to demonstrate that antibodies to m6A can induce specific mutational signatures at m6A residues after ultraviolet light-induced antibody-RNA cross-linking and reverse transcription. We found that these antibodies similarly induced mutational signatures at N(6),2'-O-dimethyladenosine (m6Am), a modification found at the first nucleotide of certain mRNAs. Using these signatures, we mapped m6A and m6Am at single-nucleotide resolution in human and mouse mRNA and identified small nucleolar RNAs (snoRNAs) as a new class of m6A-containing non-coding RNAs (ncRNAs).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nmeth.3453

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The m6A modification occurs in all types of RNA, although it has the lowest abundance in tRNA.

    “The m6A modification occurs in all types of RNA, although it has the lowest abundant in tRNA (Linder et al., 2015; Flamand et al., 2023).”

    From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Linder et al., 2015

    The Results sections on crosslinking sites and snoRNAs identify m6A in rRNA and snoRNAs, and the Abstract reports it in mRNA. Our copy does not establish that m6A occurs in all RNA types or that its abundance is lowest in tRNA; a search for tRNA abundance found no supporting passage. Page numbers were not available in the indexed copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Antibodies against m6A also recognize demethylated adenosine, m6Am.

    “Antibodies against m6A also recognize demethylated adenosine, m6Am.”

    From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Linder et al., 2015

    The Abstract reports that anti-m6A antibodies also produce mutational signatures at m6Am, supporting the claim that they recognize it. But it identifies m6Am as N6,2′-O-dimethyladenosine, not demethylated adenosine. (LLM, conf=0.91)

    Experimental — accuracy not yet measured
  • m6Am non-enzymatically converts to m6A.

    “Interestingly, m6Am also non-enzymatically converts to m6A, so the biological impact of m6Am is currently ambiguous (Linder et al., 2015; Flamand et al., 2023).”

    From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Linder et al., 2015

    The Results section, “CITS miCLIP identifies m6Am at the TSS” (page unavailable), says the function of m6Am is poorly understood, but does not say it converts to m6A. Searches for non-enzymatic conversion, demethylation, and loss of the 2′-O-methyl group found no passage addressing the claimed conversion. (LLM, conf=0.72)

    Experimental — accuracy not yet measured
  • m6Am constitutes 2-10% of total m6A detected in tissues, with brain being on the lower end of the abundance.

    “This modification constitutes 2–10% of total m6A detected in tissues, with brain being on the lower end of the abundance (Linder et al., 2015).”

    From β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer’s disease (2024) · cites this paper as Linder et al., 2015

    The Results section, “CITS miCLIP identifies m6Am at the TSS” (page unavailable), reports mapping m6Am in mRNAs but gives no 2–10% abundance estimate or tissue comparison. Searches for that percentage, relative abundance, and brain found no passage supporting the claim; the Methods describe HEK293 cells and mouse liver, not brain tissue. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. [2]Dominissini D Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq Nature 485 201 206 2012 22575960
  2. [3]Perry RP Kelley DE Friderici K Rottman F The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5′ terminus Cell 4 387 394 1975 1168101
  3. [4]Desrosiers R Friderici K Rottman F Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells Proceedings of the National Academy of Sciences of the United States of America 71 3971 3975 1974 4372599 PMC434308
  4. [5]Schibler U Kelley DE Perry RP Comparison of methylated sequences in messenger RNA and heterogeneous nuclear RNA from mouse L cells Journal of Molecular Biology 115 695 714 1977 592376
  5. [6]Schwartz S Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites Cell Reports 8 284 296 2014 24981863 PMC4142486
  6. [7]Squires JE Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA Nucleic Acids Research 40 5023 5033 2012 22344696 PMC3367185
  7. [8]Sugimoto Y Analysis of CLIP and iCLIP methods for nucleotide-resolution studies of protein-RNA interactions Genome Biology 13 R67 2012 22863408 PMC4053741
  8. [9]König J iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution Nature Structural & Molecular Biology 17 909 915 2010 PMC3000544 20601959
  9. [10]Hafner M Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP Cell 141 129 141 2010 20371350 PMC2861495
  10. [12]Schibler U Perry RP The 5′-termini of heterogeneous nuclear RNA: a comparison among molecules of different sizes and ages Nucleic Acids Research 4 4133 4149 1977 600792 PMC343230
  11. [13]Kramer K Photo-cross-linking and high-resolution mass spectrometry for assignment of RNA-binding sites in RNA-binding proteins Nature Methods 11 1064 1070 2014 25173706 PMC6485471
  12. [14]Zhang C Darnell RB Mapping in vivo protein-RNA interactions at single-nucleotide resolution from HITS-CLIP data Nat Biotechnology 29 607 614 2011 PMC3400429 21633356
  13. [15]Piekna-Przybylska D Decatur WA Fournier MJ The 3D rRNA modification maps database: with interactive tools for ribosome analysis Nucleic Acids Research 36 D178 D183 2007 17947322 PMC2238946
  14. [18]Liu N Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA RNA 19 1848 1856 2013 24141618 PMC3884656
  15. [20]Ni T A paired-end sequencing strategy to map the complex landscape of transcription initiation Nature Methods 7 521 527 2010 20495556 PMC3197272
  16. [21]Plessy C Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan Nature Methods 7 528 534 2010 20543846 PMC2906222
  17. [22]Bailey TL MEME SUITE: tools for motif discovery and searching Nucleic Acids Research 37 W202 W208 2009 19458158 PMC2703892
  18. [23]Frith MC A code for transcription initiation in mammalian genomes Genome Research 18 1 12 2008 18032727 PMC2134772
  19. [24]Moss B Gershowitz A Weber LA Baglioni C Histone mRNAs contain blocked and methylated 5′ terminal sequences but lack methylated nucleosides at internal positions Cell 10 113 120 1977 837441
  20. [25]Schwartz S Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA Cell 159 148 162 2014 25219674 PMC4180118
  21. [26]Chen K High-resolution N6-methyladenosine (m6A) map using photo-crosslinking-assisted m6A sequencing Angewandte Chemie International Edition 54 1587 1590 2014 PMC4396828 25491922
  22. [28]Graham JM Isolation of nuclei and nuclear membranes from animal tissues Current Protocols in Cell Biology 3 10 2001 18228353
  23. [29]Dodt M Roehr JT Ahmed R Dieterich C FLEXBAR—flexible barcode and adapter processing for next-generation sequencing platforms Biology 1 895 905 2012 24832523 PMC4009805
  24. [30]Webb S Hector RD Kudla G Granneman S PAR-CLIP data indicate that Nrd1-Nab3-dependent transcription termination regulates expression of hundreds of protein coding genes in yeast Genome Biology 15 R8 2014 24393166 PMC4053934
  25. [31]Heinz S Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities Molecular Cell 38 576 589 2010 20513432 PMC2898526

Cited by

Sorted by citations

Authors
Linder, B., Grozhik, A. V., Olarerin-George, A. O., Meydan, C., Mason, C. E., & Jaffrey, S. R.
Affiliations
Cornell University (US)
Corresponding author
Jaffrey, Samie R
Venue
Nature Methods
Published
2015-06-29
Volume
12
Issue
8
Pages
767-772
ISSN
  • 1548-7091 (ISSN-L)
  • 1548-7105
OpenAlex
W776567260
Cited by
1,569
References
5
Citations by year
2026: 111 · 2025: 156 · 2024: 203 · 2023: 179 · 2022: 174 · 2021: 211 · 2020: 173 · 2019: 132 · 2018: 100 · 2017: 77 · 2016: 46 · 2015: 7
FWCI
33.31
Type
journal article
Language
en
Open access
Locations
  • Nature Methods (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Drug Abuse (R01DA037150, DA037150)
  • National Cancer Institute (T32CA062948)
  • National Institute of Neurological Disorders and Stroke (NS076465, R01NS076465)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD060600)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Keywords
N6-methyladenosine, mRNA methylation, UV crosslinking, small nucleolar RNA
MeSH terms
Adenosine, Animals, Antibodies, Cross-Linking Reagents, DNA Mutational Analysis, Humans, Methylation, Mutation, Nucleotide Mapping, RNA, Messenger, Transcription, Genetic, Ultraviolet Rays, Sequence Analysis, DNA, RNA, Small Nucleolar, Mice, HEK293 Cells, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review